HUP0102501A2 - Karnitint és glutationt tartalmazó, a glutation abszorpcióját fokozó és hatását erősítő készítmény - Google Patents

Karnitint és glutationt tartalmazó, a glutation abszorpcióját fokozó és hatását erősítő készítmény

Info

Publication number
HUP0102501A2
HUP0102501A2 HU0102501A HUP0102501A HUP0102501A2 HU P0102501 A2 HUP0102501 A2 HU P0102501A2 HU 0102501 A HU0102501 A HU 0102501A HU P0102501 A HUP0102501 A HU P0102501A HU P0102501 A2 HUP0102501 A2 HU P0102501A2
Authority
HU
Hungary
Prior art keywords
glutathione
carnitine
absorption
composition
synergize
Prior art date
Application number
HU0102501A
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Sigma-Tau Healthscience S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Healthscience S.P.A. filed Critical Sigma-Tau Healthscience S.P.A.
Publication of HUP0102501A2 publication Critical patent/HUP0102501A2/hu
Publication of HUP0102501A3 publication Critical patent/HUP0102501A3/hu
Publication of HU229272B1 publication Critical patent/HU229272B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány kombinált készítményre vonatkozik, mely (a) propionil-L-karnitint vagy gyógyászatilag elfogadható sóját; és (b) glutationtvagy glutation-tartalmú élesztőt; (c) abban az esetben, ha (b)komponens glutation, glutation-mentes élesztőt tartalmaz. A készítményrendkívül hatásos a metabolikusan legaktívabb szervek, így példáulmáj, vese, szív- és érrendszer, valamint agy rendellenességeinekmegelőzésére és/vagy kezelésére a komponensek által kifejtett erősszinergikus hatásnak, valamint a szövetekbe történő fokozott mértékűfelvételüknek - különösen a glutationénak - köszönhetően. A találmányszerinti készítmény lehet táplálék-kiegészítő vagy valódi gyógyszerformájában a kezelendő személy állapotától függően. Ó
HU0102501A 1999-04-16 2000-04-07 Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects HU229272B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999RM000230A IT1306130B1 (it) 1999-04-16 1999-04-16 Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti.
PCT/IT2000/000129 WO2000062773A1 (en) 1999-04-16 2000-04-07 Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects

Publications (3)

Publication Number Publication Date
HUP0102501A2 true HUP0102501A2 (hu) 2001-11-28
HUP0102501A3 HUP0102501A3 (en) 2002-12-28
HU229272B1 HU229272B1 (en) 2013-10-28

Family

ID=11406677

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102501A HU229272B1 (en) 1999-04-16 2000-04-07 Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects

Country Status (25)

Country Link
US (1) US6306392B1 (hu)
EP (1) EP1087762B1 (hu)
JP (1) JP2002542191A (hu)
KR (1) KR20010071467A (hu)
CN (1) CN1300214A (hu)
AR (1) AR033325A1 (hu)
AT (1) ATE282409T1 (hu)
AU (1) AU774191B2 (hu)
BR (1) BR0006045A (hu)
CA (1) CA2334919C (hu)
DE (1) DE60015893T2 (hu)
EE (1) EE200000732A (hu)
ES (1) ES2232443T3 (hu)
HU (1) HU229272B1 (hu)
IL (1) IL139851A0 (hu)
IS (1) IS5740A (hu)
IT (1) IT1306130B1 (hu)
NO (1) NO20006285L (hu)
NZ (1) NZ509276A (hu)
PL (1) PL213130B1 (hu)
PT (1) PT1087762E (hu)
SK (1) SK18852000A3 (hu)
TN (1) TNSN00077A1 (hu)
TR (1) TR200003688T1 (hu)
WO (1) WO2000062773A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306147B1 (it) * 1999-05-28 2001-05-30 Biosalts Srl Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
IT1316997B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di vasculopatie,che comprende propionil l-carnitina e coenzima q10.
IT1316998B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
KR100528720B1 (ko) * 2002-08-29 2005-11-15 주식회사 메디넥스 중금속 제거용 특수 영양식품
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
JP5785355B2 (ja) * 2004-11-24 2015-09-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物における生体異物物質の肝臓クリアランスを改良する方法
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
CN101128109B (zh) 2004-12-30 2013-07-03 希尔氏宠物营养品公司 提高老年动物的生活质量的方法
AU2006219823A1 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
US8492432B2 (en) * 2005-08-17 2013-07-23 Hill's Pet Nutrition, Inc. Methods for the treatment of kidney disease
JP4831540B2 (ja) * 2005-08-26 2011-12-07 株式会社興人 経口催眠剤及び催眠性飲食物
JP2009107962A (ja) * 2007-10-29 2009-05-21 Asahi Breweries Ltd 酵母エキス含有組成物
AU2009315771A1 (en) * 2008-11-11 2010-05-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compound useful for treating cellulite
CN103535721B (zh) * 2013-09-27 2016-04-06 美国东方生物技术（香港）有限公司 提高人体内谷胱甘肽浓度的组合物及其制备方法和应用
CN103478718B (zh) * 2013-09-27 2015-10-28 美国东方生物技术（香港）有限公司 提高人体内谷胱甘肽浓度的功能食品及其制备方法
CN103750344B (zh) * 2014-01-25 2015-11-04 北京凯因科技股份有限公司 一种酵母谷胱甘肽营养配制品
IL261670B (en) * 2018-09-06 2019-06-30 Tudu Holdings Ltd Magnesium-containing formulation and uses thereof
JP7478517B2 (ja) * 2019-04-24 2024-05-07 三菱商事ライフサイエンス株式会社 脂質活性代謝改善組成物
KR102559814B1 (ko) * 2021-05-14 2023-07-26 가톨릭대학교 산학협력단 글루타치온을 유효성분으로 포함하는 신장질환 치료용 약학적 조성물
KR102535328B1 (ko) * 2022-10-18 2023-05-26 주식회사 청안오가닉스 흑후추 추출물을 함유하여 글루타치온의 체내 흡수율을 높인 건강기능 식품용 조성물 및 이의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283951B1 (it) * 1996-03-15 1998-05-07 Mendes Srl Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito

Also Published As

Publication number Publication date
IL139851A0 (en) 2002-02-10
US6306392B1 (en) 2001-10-23
ITRM990230A1 (it) 2000-10-16
BR0006045A (pt) 2001-03-13
TNSN00077A1 (fr) 2002-05-30
AU4311700A (en) 2000-11-02
IT1306130B1 (it) 2001-05-30
AU774191B2 (en) 2004-06-17
KR20010071467A (ko) 2001-07-28
EP1087762B1 (en) 2004-11-17
PL213130B1 (pl) 2013-01-31
HU229272B1 (en) 2013-10-28
CA2334919A1 (en) 2000-10-26
PL344790A1 (en) 2001-11-19
WO2000062773A1 (en) 2000-10-26
DE60015893T2 (de) 2005-12-01
EP1087762A1 (en) 2001-04-04
ATE282409T1 (de) 2004-12-15
DE60015893D1 (de) 2004-12-23
EE200000732A (et) 2002-06-17
CN1300214A (zh) 2001-06-20
CA2334919C (en) 2009-02-24
NO20006285L (no) 2001-02-12
IS5740A (is) 2000-11-28
JP2002542191A (ja) 2002-12-10
NO20006285D0 (no) 2000-12-11
PT1087762E (pt) 2005-03-31
AR033325A1 (es) 2003-12-17
NZ509276A (en) 2002-09-27
ES2232443T3 (es) 2005-06-01
HUP0102501A3 (en) 2002-12-28
SK18852000A3 (sk) 2001-06-11
TR200003688T1 (tr) 2001-06-21

Similar Documents

Publication Publication Date Title
HUP0102501A2 (hu) Karnitint és glutationt tartalmazó, a glutation abszorpcióját fokozó és hatását erősítő készítmény
EA200200392A1 (ru) Способ получения экстракта из растения рода trichocaulon или рода hoodia, экстракт, порошковый материал и композиция на его основе и их применение для производства медикамента для лечения, профилактики или преодоления ожирения и/или подавления аппетита
WO2003051313A3 (en) Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
NO952863D0 (no) Fluoxetin-farmasöytiske sammensetninger
NO20100061L (no) Forhindring og behandling av amyloidogen sykdom
JP2002138045A (ja) 前駆脂肪細胞分化誘導剤
JPH1053532A (ja) 植物抽出物含有抗アレルギー剤
CA2374958A1 (en) Compositions normalizing circadian rhythm
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
NO20020337L (no) Preparat for forebyggelse av muskelutmattelse og skjelettmuskeltilpasning til anstrengende utövelse
EP0680945A3 (en) Amino acid, carnitine and magnesium supplementation
HUP0102926A2 (hu) Karnitint és inozit-foszfátot tartalmazó, táplálékkiegészítőként vagy gyógyszerként alkalmazható készítmény
TR200200948T2 (tr) L-karnitin türevlerini ve ginkgo biloba özlerini içeren bileşim
JP2000302634A (ja) 化粧料組成物
JP2002104924A (ja) 光老化防御剤
CA2060560A1 (en) Method for insuring adequate intracellular glutathione in tissue
JPH10203994A (ja) 生理活性作用組成物
JP2002068953A (ja) 化粧料組成物
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
JP2004238310A (ja) 化粧料組成物又は飲食品
JP2000281528A (ja) 化粧料組成物
JP2009023922A (ja) 肩こり・五十肩・各種関節痛等の改善を目的とした塗布剤
TR200200224T2 (tr) Böbrek bozukluğu ve hastalıklarının önlenmesi ve tedavisi için bileşim
JP2003081868A (ja) ストレス抑制剤
JPH104953A (ja) メラトニン酵母を利用した美容・健康向け組成物

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P., IT

Free format text: FORMER OWNER(S): SIGMA-TAU HEALTHSCIENCE S.P.A., IT

MM4A Lapse of definitive patent protection due to non-payment of fees